Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 38 sources its claims cite were checked for support.

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Open access

Abstract

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. Adverse events and suicidality were tracked throughout the study. MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was -24.4 (s.d. 11.6) in the MDMA group and -13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation.

Overview

CoChat Summary

TL;DR

This randomized, double-blind, placebo-controlled phase 3 trial found that MDMA-assisted therapy significantly reduced PTSD severity and functional impairment over 18 weeks in people with severe PTSD. The treatment also showed benefits for depressive symptoms and did not increase suicidality or major safety problems in the MDMA arm.

Key findings

  • Among 91 randomized participants (46 MDMA, 44 placebo; one participant did not provide post-dose data), MDMA produced a greater reduction in CAPS-5 PTSD severity than placebo: between-group difference = 11.9, 95% CI 6.3–17.4, P < 0.0001; effect size d = 0.91.
  • Functional impairment also improved more with MDMA than placebo on the SDS: P = 0.0116; effect size d = 0.43.
  • In completers, CAPS-5 change from baseline to 18 weeks was −24.4 (s.d. 11.6) with MDMA versus −13.9 (s.d. 11.5) with placebo.
  • Exploratory results showed greater reduction in depressive symptoms on the BDI-II with MDMA (mean Δ = −19.7, s.d. 14.0; placebo mean Δ = −10.8, s.d. 11.3; P = 0.0026; d = 0.67), and at 18 weeks 67% (28/42) of MDMA participants no longer met PTSD criteria versus 32% (12/37) on placebo; remission was 33% (14/42) versus 5% (2/37).

Methods

  • Multisite randomized, double-blind, placebo-controlled phase 3 trial at 15 sites in the United States, Canada, and Israel; participants received MDMA-assisted therapy or placebo with identical manualized therapy.
  • Adults with current DSM-5 PTSD for at least 6 months and baseline CAPS-5 severity ≥35 were enrolled after psychiatric medication washout; 90 participants were included in the modified intent-to-treat analysis, and 42 MDMA/37 placebo were completers.
  • Primary and secondary outcomes (CAPS-5 and SDS) were assessed by blinded independent raters using MMRM, with a de jure estimand for efficacy; safety events, suicidality, and adverse events were tracked throughout.

Limitations

  • The paper states that the participant population was smaller than originally planned because of the COVID-19 pandemic, although it argues the study still had sufficient power.
  • The population was relatively homogeneous and lacked racial and ethnic diversity, which the authors say should be addressed in future trials.
  • The authors note that safety data were collected by site therapists, which may have limited blinding; they also say participant blinding was challenging because of MDMA’s subjective effects, and at unblinding at least 10% guessed incorrectly (at least 7/44 placebo participants thought they received MDMA; at least 2/46 MDMA participants thought they received placebo).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01336-3

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Procedure timeline and study flow diagram. a, Procedure timeline. Following the screening procedures and medication taper, participants attended a total of three preparatory sessions, three experimental sessions, nine integration sessions and four endpoint assessments (T1–4) over 18 weeks, concluding with a final study-termination visit. IR, independent rater; T, timepoint of endpoint assessment; T1, baseline; T2, after the first experimental session; T3, after the second experimental session; T4, 18 weeks after baseline. b, CONSORT diagram indicating participant numbers and disposition through the course of the trial.
Fig. 1 Procedure timeline and study flow diagram. a, Procedure timeline. Following the screening procedures and medication taper, participants attended a total of three preparatory sessions, three experimental sessions, nine integration sessions and four endpoint assessments (T1–4) over 18 weeks, concluding with a final study-termination visit. IR, independent rater; T, timepoint of endpoint assessment; T1, baseline; T2, after the first experimental session; T3, after the second experimental session; T4, 18 weeks after baseline. b, CONSORT diagram indicating participant numbers and disposition through the course of the trial.CC BY · PubMed Central
Fig. 2 Measures of MDMA efficacy in the MDMA-assisted therapy group and the placebo group. a, Change in CAPS-5 total severity score from T1 to T4 (P < 0.0001, d = 0.91, n = 89 (MDMA n = 46)), as a measure of the primary outcome. Primary analysis was completed using least square means from an MMRM model. b, Change in SDS total score from T1 to T4 (P = 0.0116, d = 0.43, n = 89 (MDMA n = 46)), as a measure of the secondary outcome. Primary analysis was completed using least square means from an MMRM model. c, Change in BDI-II score from T1 to study termination (t = −3.11, P = 0.0026, n = 81 (MDMA n = 42)), as a measure of the exploratory outcome. Data are presented as mean and s.e.m.
Fig. 2 Measures of MDMA efficacy in the MDMA-assisted therapy group and the placebo group. a, Change in CAPS-5 total severity score from T1 to T4 (P < 0.0001, d = 0.91, n = 89 (MDMA n = 46)), as a measure of the primary outcome. Primary analysis was completed using least square means from an MMRM model. b, Change in SDS total score from T1 to T4 (P = 0.0116, d = 0.43, n = 89 (MDMA n = 46)), as a measure of the secondary outcome. Primary analysis was completed using least square means from an MMRM model. c, Change in BDI-II score from T1 to study termination (t = −3.11, P = 0.0026, n = 81 (MDMA n = 42)), as a measure of the exploratory outcome. Data are presented as mean and s.e.m.CC BY · PubMed Central
Fig. 3 Treatment response and remission for MDMA and placebo groups as a percentage of total participants randomized to each arm (MDMA, n = 46; placebo, n = 44). Responders (clinically significant improvement, defined as a ≥10-point decrease on CAPS-5), loss of diagnosis (specific diagnostic measure on CAPS-5), and remission (loss of diagnosis and a total CAPS-5 score of ≤11) were tracked in both groups. Non-response is defined as a <10-point decrease on CAPS-5. Withdrawal is defined as a post-randomization early termination.
Fig. 3 Treatment response and remission for MDMA and placebo groups as a percentage of total participants randomized to each arm (MDMA, n = 46; placebo, n = 44). Responders (clinically significant improvement, defined as a ≥10-point decrease on CAPS-5), loss of diagnosis (specific diagnostic measure on CAPS-5), and remission (loss of diagnosis and a total CAPS-5 score of ≤11) were tracked in both groups. Non-response is defined as a <10-point decrease on CAPS-5. Withdrawal is defined as a post-randomization early termination.CC BY · PubMed Central
Fig. 4 Number of participants reporting the presence of suicidal ideation as measured with the C-SSRS at each visit and separated by treatment group. C-SSRS ideation scores range from 0 (no ideation) to 5. A C-SSRS ideation score of 4 or 5 is termed ‘serious ideation’. The number of participants endorsing any positive ideation (>0) is shown by the colored bars and noted in the table below the graph. The number of participants endorsing serious ideation is given in parentheses in the table.
Fig. 4 Number of participants reporting the presence of suicidal ideation as measured with the C-SSRS at each visit and separated by treatment group. C-SSRS ideation scores range from 0 (no ideation) to 5. A C-SSRS ideation score of 4 or 5 is termed ‘serious ideation’. The number of participants endorsing any positive ideation (>0) is shown by the colored bars and noted in the table below the graph. The number of participants endorsing serious ideation is given in parentheses in the table.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 2 Not valid · 18 Not checked · 86 Own results and interpretations

47 more claims · 2 with their cited sources checked

Create a free account to see all 113 claims and to verify the 29 references still open.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 34

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

2 retracted

Show all 37 references

Cited by

See all 1,004

Metadata

Authors
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., Amiaz, R., Worthy, R., Shannon, S., Woolley, J. D., Marta, C., Gelfand, Y., Hapke, E., Amar, S., Wallach, Y., Brown, R., Hamilton, S., Wang, J. B., Coker, A., Matthews, R., de Boer, A., Yazar-Klosinski, B., Emerson, A., & Doblin, R.
Affiliations
  • University of California, San Francisco (US)
  • New York University (US)
  • Multidisciplinary Association for Psychedelic Studies (US)
  • University of Colorado Boulder (US)
  • Fluent (United States) (US)
  • University of Wisconsin–Madison (US)
  • Medical University of South Carolina (US)
  • British Columbia Centre on Substance Use (CA)
  • Sheba Medical Center (IL)
  • University of Toronto (CA)
  • Stanford Medicine (US)
Corresponding author
Mitchell, Jennifer M.
Venue
Nature Medicine
Published
2021-05-10
Volume
27
Issue
6
Pages
1025-1033
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3160990818
Cited by
1,004
References
37
Citations by year
2026: 150 · 2025: 195 · 2024: 215 · 2023: 212 · 2022: 181 · 2021: 48
FWCI
111.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
Multidisciplinary Association for Psychedelic Studies
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, psychedelic-assisted psychotherapy, dissociation, depression, substance use disorders, childhood trauma, treatment efficacy, treatment safety, suicidality, QT prolongation, functional disability, comorbidities
MeSH terms
Adult, Combined Modality Therapy, Double-Blind Method, Female, Humans, Male, Middle Aged, Stress Disorders, Post-Traumatic, Treatment Outcome, N-Methyl-3,4-methylenedioxyamphetamine, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. https://app.cochat.ai/papers/10.1038/s41591-021-01336-3
The paper
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., . . . Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. https://doi.org/10.1038/s41591-021-01336-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.